Psychological disorders, such as depression, bipolar, and anxiety disorders can present several complications for patients of all ages. These disorders affect patients physically and emotionally, potentially impacting judgment, school and/or job performance, and relationships with family and friends. Since these disorders have many drastic effects on patients’ lives, it is important for advanced practice nurses to effectively manage patient care. With patient factors and medical history in mind, it is the advanced practice nurse’s responsibility to ensure the safe and effective diagnosis, treatment, and education of patients with psychological disorders.

Generalized Anxiety Disorder is a psychological condition that affects 6.1 million Americans, or 3.1% of the US Population. Despite several treatment options, only 43.2% of those suffering from GAD receive treatment. This week you will review several different classes of medication used in the treatment of Generalized Anxiety Disorder. You will examine potential impacts of pharmacotherapeutics used in the treatment of GAD. Please focus your assignment on FDA approved indications when referring to different medication classes used in the treatment of GAD.

To Prepare:

• Review the Resources for this module and consider the principles of pharmacokinetics and pharmacodynamics.
• Reflect on your experiences, observations, and/or clinical practices from the last 5 years and think about how pharmacokinetic and pharmacodynamic factors altered his or her anticipated response to a drug.
• Consider factors that might have influenced the patient’s pharmacokinetic and pharmacodynamic processes, such as genetics (including pharmacogenetics), gender, ethnicity, age, behavior, and/or possible pathophysiological changes due to disease.
• Think about a personalized plan of care based on these influencing factors and patient history with GAD.

BY  DAY 3 OF WEEK 8:

Post a discussion of pharmacokinetics and pharmacodynamics related to anxiolytic medications used to treat GAD. In your discussion, utilizing the discussion highlights, compare and contrast different treatment options that can be used.

BY DAY6 OF WEEK 8:

Read a selection of your colleagues’ responses and respond to at least two of your colleagues on two different days by suggesting additional factors that might have interfered with the pharmacokinetic and pharmacodynamic processes of the patients diagnosed with GAD. In addition, suggest different treatment options you would suggest to treat a patient with the topic of discussion.

SOLUTION:

Generalized anxiety disorder (GAD) is a chronic illness in which the individual may begin. in early adulthood or even adolescence and is persistent throughout the life of the individual. Common observable behaviors are, excessive worry about everyday situations, somatic and physical symptoms. There are several research models for providing treatment. Considered pharmacotherapy treatments in patients with comorbidities (Major depression, alcohol dependence) and of course the age of the individual; to include the use of selective. serotonin and norepinephrine reuptake inhibitors (SSRI and SSNI) as well benzodiazepines, antiadrenergic medications Second-generation antipsychotics Kava and lavender oil. Research by Strawn (2018), and associates Identified psychotherapy in combination with pharmacotherapy. Both working together, psychotherapy increases adherence and mitigating. effects negative outcomes of pharmacotherapy.Selective serotonin re-uptake (SSRI) transporter impedes dopamine and norepinephrine re-uptake. process. Medications commonly prescribed: Fluoxetine, increases serotonin transmission, metabolized in the CYP2D6 yet inhibits activity and has a half-life of 4-6 days. Sertraline,

which has a peak serum level in 6 to 8 hours. After 4 to 8 weeks of (treatment improvement in symptoms are seen based on a half-life of 26 to 36 hours well studies suggest that twice daily. Administration is required. Paroxetine which stops 5-HT re-uptake and additionally blocking re[1]uptake of norepinephrine and is supported by three double blind studies as being well tolerated for treating GAD. and citalopram a protein bound SSRI metabolized through the CYP2C19 and.……………………KINDLY CLICK ON THE PURCHASE ICON BELOW TO ACCESS THE ENTIRES SOLUTION FOR $12